KINAXO Announces Agreement with Johnson & Johnson Pharmaceutical Research & Development

Martinsried, Germany, January 11, 2007. KINAXO Biotechnologies GmbH announced today that it has entered an agreement with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica N.V., Beerse, Belgium. Under the agreement, KINAXO will use the KinaTorTM technology to perform target selectivity analyses for selected J&JPRD small molecule compounds.

The KinaTorTM technology uses immobilized small molecule inhibitors to detect their protein binding partners in biological samples. Small molecule-protein interactions are identified by a combination of sophisticated affinity-based separation procedures and sensitive mass spectrometry. The KinaTorTM provides tailor-made solutions for various problems in drug development, such as the identification of previously unknown disease-relevant targets as well as off-target related toxicities.

About KINAXO

KINAXO is a spin-off from the Max Planck Institute of Biochemistry in Martinsried, initiated by Prof. Dr. Axel Ullrich and Dr. Henrik Daub as well as Max Planck Innovation GmbH, the technology transfer center of the Max Planck Society. KINAXO offers a comprehensive chemical proteomics technology - known as KinaTorTM - to identify and characterize the biological interaction of small molecule inhibitors with their protein targets in the physiological context of a cell.

Contact Information

Dr. Andreas Jenne

CEO

KINAXO Biotechnologies GmbH

Contact via E-mail